RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Athira Pharma Stock

Athira Pharma P/E 2024

Athira Pharma P/E

-0.97

Ticker

ATHA

ISIN

US04746L1044

WKN

A2QCFW

As of Nov 5, 2024, Athira Pharma's P/E ratio was -0.97, a 8.99% change from the -0.89 P/E ratio recorded in the previous year.

The Athira Pharma P/E history

Athira Pharma Aktienanalyse

What does Athira Pharma do?

Athira Pharma Inc. is a biopharmaceutical company founded in 2011 and based in Seattle, USA. The company focuses on the development of therapies for neurodegenerative diseases such as Alzheimer's and Parkinson's. The strategy of Athira is to develop therapies for the treatment of diseases of the central nervous system and the regeneration of tissues that have been damaged by injuries or aging, based on RNA-based technologies. This work is carried out by an experienced team of scientists and executives. Athira's business model is based on the goal of developing innovative and personalized drug therapies to prevent, slow down, or specifically treat diseases. The company pursues an evidence-based approach called "patient-centered approach." Athira aims to understand the cause of certain diseases and develop targeted therapies that aim to treat that cause. Athira's research and development area consists of three units: 1. Neurology: This division focuses on the development of therapies for the treatment of neurodegenerative diseases such as Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis. The company has already developed a drug candidate that is in an extended phase I/II clinical trial and shows potential for the treatment of Alzheimer's dementia. 2. Regeneration: The regeneration division mainly deals with the regeneration of nerve cells and tissues in the body. This area has the potential to develop therapies for the treatment of spinal cord injuries and degenerative diseases of the body. 3. Platform technology: Athira's platform technologies are based on RNA interference technology, which aims to experimentally silence genes. The platform technology aims to identify and validate cell-specific RNA targets that can address a wide range of diseases. Athira specializes in the research and development of innovative therapies with the goal of defeating diseases and improving patients' health. The company has achieved significant successes in recent years, positioning itself as an important player in the industry. The market for therapies for the treatment of neurodegenerative diseases offers immense opportunities and potentials as these diseases are expected to increase in the future due to the aging population. Athira sees itself well positioned to take on the challenges in the industry and continue to develop innovative solutions for the treatment of diseases. Athira Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Athira Pharma's P/E Ratio

The Price to Earnings (P/E) Ratio of Athira Pharma is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Athira Pharma's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Athira Pharma is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Athira Pharma’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Athira Pharma stock

What is the price-to-earnings ratio of Athira Pharma?

The price-earnings ratio of Athira Pharma is currently -0.97.

How has the price-earnings ratio of Athira Pharma changed compared to last year?

The price-to-earnings ratio of Athira Pharma has increased by 8.99% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Athira Pharma high compared to other companies?

Yes, the price-to-earnings ratio of Athira Pharma is high compared to other companies.

How does an increase in the price-earnings ratio of Athira Pharma affect the company?

An increase in the price-earnings ratio of Athira Pharma would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Athira Pharma affect the company?

A decrease in the price-earnings ratio of Athira Pharma would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Athira Pharma?

Some factors that influence the price-earnings ratio of Athira Pharma are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Athira Pharma pay?

Over the past 12 months, Athira Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Athira Pharma is expected to pay a dividend of 0 USD.

What is the dividend yield of Athira Pharma?

The current dividend yield of Athira Pharma is .

When does Athira Pharma pay dividends?

Athira Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Athira Pharma?

Athira Pharma paid dividends every year for the past 0 years.

What is the dividend of Athira Pharma?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Athira Pharma located?

Athira Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Athira Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Athira Pharma from 11/5/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/5/2024.

When did Athira Pharma pay the last dividend?

The last dividend was paid out on 11/5/2024.

What was the dividend of Athira Pharma in the year 2023?

In the year 2023, Athira Pharma distributed 0 USD as dividends.

In which currency does Athira Pharma pay out the dividend?

The dividends of Athira Pharma are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Athira Pharma

Our stock analysis for Athira Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Athira Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.